Human VEGF R2/KDR Quantikine ELISA Kit

(24 citations)
(1 Review)
  
  • Assay Type
    Solid Phase Sandwich ELISA
  • Format
    96-well strip plate
  • Assay Length
    4.5 hours
  • Sample Type & Volume Required Per Well
    Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (20 uL), EDTA Plasma (20 uL), Heparin Plasma (20 uL)
  • Sensitivity
    11.4 pg/mL
  • Assay Range
    78.1 - 5,000 pg/mL (Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma)
  • Specificity
    Natural and recombinant human VEGF R2
  • Cross-reactivity
    < 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
  • Interference
    Interference observed with 1 or more available related molecules.
Control Available
QC05, Quantikine Immunoassay Control Group 2 - Please Inquire
Product Summary
The Quantikine Human VEGF R2 Immunoassay is a 4.5 hour solid-phase Immunoassay designed to measure human soluble VEGF R2 in cell culture supernates, cell lysates, serum, and plasma. It contains NS0-expressed recombinant human VEGF R2/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R2 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human soluble VEGF R2.

Precision
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.
Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma
Intra-Assay Precision Inter-Assay Precision
Sample123123
n202020404040
Mean4651269299545512332962
Standard Deviation19.445.587.932.184.8169
CV%4.23.62.976.95.7

Recovery

The recovery of VEGF R2 spiked to levels throughout the range of the assay was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 99 92-104
Linearity
To assess the linearity of the assay, samples containing high concentrations of VEGF R2 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human VEGF R2/KDR Quantikine ELISA Kit
Preparation and Storage
  • Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: VEGF R2/KDR/Flk-1
VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.
    • Long Name
      Vascular Endothelial Growth Factor Receptor 2
    • Entrez Gene IDs
      3791 (Human); 16542 (Mouse);
    • Alternate Names
      CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2;
    Related Research Areas
    Assay Procedure
    Refer to the product for complete assay procedure.

    Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
    1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
    2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

    3. 100 µL Assay Diluent
    4.   Add 100 µL of Assay Diluent to each well.

    5. 100 µL Standard, Control, or Sample
    6.   Add 100 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
    7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

    8. 200 µL Conjugate
    9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours.
    10.   Aspirate and wash 4 times.

    11. 200 µL Substrate Solution
    12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.

    13. 50 µL Stop Solution
    14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.
    Citations:

    R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

    24 Citations: Showing 1 - 10
    Filter your results:

    Species
    Sample Type
    1. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants
      Authors: J Sánchez Ra, Y Morera Día, M Bequet-Rom, F Hernández-, KH Selman-Hou, A de la Torr, ER Santiesteb, Y Martín Bau, CH Bermúdez B, J de la Torr, JV Gavilondo,, M Ayala Avil
      BMC Immunol., 2017;18(1):39.
      Species: Human
      Sample Type: Serum
    2. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
      Authors: Salazar R, Capdevila J, Laquente B, Manzano J, Pericay C, Villacampa M, Lopez C, Losa F, Safont M, Gomez A, Alonso V, Escudero P, Gallego J, Sastre J, Gravalos C, Biondo S, Palacios A, Aranda E
      BMC Cancer, 2015;15(0):60.
      Species: Human
      Sample Type: Plasma
    3. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
      Authors: Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M
      BMC Cancer, 2014;14(0):696.
      Species: Human
      Sample Type: Serum
    4. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
      Authors: Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz L, Morosi C, Crippa F, Fare E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud F, Salvioni R, Daidone M, Gianni A, Mariani L
      Br J Cancer, 2014;110(1):26-33.
      Species: Human
      Sample Type: Plasma
    5. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy.
      Authors: Abu El-Asrar, Ahmed M, Nawaz, Mohd Imt, Kangave, Dustan, Mairaj Siddiquei, Mohammed, Geboes, Karel
      J Diabetes Res, 2013;0(0):539658.
      Species: Human
      Sample Type: Vitreous Humor
    6. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
      Authors: Briasoulis, Evangelo, Aravantinos, Gerasimo, Kouvatseas, George, Pappas, Periklis, Biziota, Eirini, Sainis, Ioannis, Makatsoris, Thomas, Varthalitis, Ioannis, Xanthakis, Ioannis, Vassias, Antonios, Klouvas, George, Boukovinas, Ioannis, Fountzilas, George, Syrigos, Kostanti, Kalofonos, Haralamb, Samantas, Epaminon
      BMC Cancer, 2013;13(1):263.
      Species: Human
      Sample Type: Plasma
    7. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
      Authors: Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, Rybicki A, Sy O, Vahdat L, Cortes J
      Clin Cancer Res, 2013;19(7):1884-93.
      Species: Human
      Sample Type: Plasma
    8. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
      Authors: Jurgensmeier J, Schmoll H, Robertson J, Brooks L, Taboada M, Morgan S, Wilson D, Hoff P
      Br J Cancer, 2013;108(6):1316-23.
      Species: Human
      Sample Type: Plasma
    9. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
      Authors: Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, Glade Bender J, Burke M, Weigel B, Stempak D, Balis F, Blaney S
      Clin Cancer Res, 2012;18(21):6011-22.
      Species: Human
      Sample Type: Plasma
    10. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
      Br. J. Cancer, 2012;107(4):639-45.
      Species: Human
      Sample Type: Serum
    11. Prognostic significance of angiogenic factors in uterine cervical cancer.
      Authors: Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S
      Anticancer Res., 2011;31(8):2589-95.
      Species: Human
      Sample Type: Serum
    12. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
      Authors: Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B
      Br. J. Cancer, 2011;104(7):1144-50.
      Species: Human
      Sample Type: Plasma
    13. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
      Authors: Loupakis F, Cremolini C, Fioravanti A
      Br. J. Cancer, 2011;104(8):1262-9.
      Species: Human
      Sample Type: Plasma
    14. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
      Authors: Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S
      J Transl Med, 2011;9(0):120.
      Species: Human
      Sample Type: Plasma
    15. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
      Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
      Clin. Cancer Res., 2011;17(15):5113-22.
      Species: Human
      Sample Type: Plasma
    16. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept.
      Authors: de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, Deangelis L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Heymach JV
      Clin. Cancer Res., 2011;17(14):4872-4881.
      Species: Human
      Sample Type: Plasma
    17. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
      Authors: Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M
      Fertil. Steril., 2010;94(1):52-7.
      Species: Human
      Sample Type: Serum
    18. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
      Authors: Konings IR, de Jonge MJ, Burger H
      Br. J. Cancer, 2010;103(7):987-92.
      Species: Human
      Sample Type: Serum
    19. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
      Authors: Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S
      Mol. Ther., 2009;17(2):278-84.
      Species: Human
      Sample Type: Plasma
    20. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
      Authors: Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK
      J. Clin. Oncol., 2009;27(18):3027-35.
      Species: Human
      Sample Type: Plasma
    21. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
      Authors: Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD
      J. Clin. Oncol., 2008;26(11):1810-6.
      Species: Human
      Sample Type: Plasma
    22. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction.
      Authors: Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D
      Clin. Sci., 2007;112(1):51-7.
      Species: Human
      Sample Type: Serum
    23. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
      Authors: Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV
      Clin. Cancer Res., 2007;13(9):2643-50.
      Species: Human
      Sample Type: Plasma
    24. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
      Authors: Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ
      J. Clin. Oncol., 2007;25(30):4793-9.
      Species: Human
      Sample Type: Plasma
    Expand to show all 24 Citations
    ELISA Controls
    Description Application Cat# Citations Images  

    Quantikine Immunoassay Control Group 2

    Ctrl QC05
    View Sizes & Prices
    Catalog# Size Price Stock Quantity
    Loading Information....
    Supplemental ELISA Products
    Description Application Cat# Citations Images  

    Quantikine ELISA Wash Buffer 1

    ELISA WA126 6
    View Sizes & Prices
    Catalog# Size Price Stock Quantity
    Loading Information....

    Cell Lysis Buffer 2

    ELISA 895347 2
    View Sizes & Prices
    Catalog# Size Price Stock Quantity
    Loading Information....
    Average Rating: 5 (Based on 1 review)

    Have you used Human VEGF R2/KDR Quantikine ELISA Kit?

    Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

    Read what people are saying who have used Human VEGF R2/KDR Quantikine ELISA Kit.

    Filter by Ratings
    Excellent
    (1)
    All Ratings
    Filter by Applications
    All Applications
    Filter by Species
    All Species

    Images Ratings Applications Species Reviewed By Date Details
     Human VEGF R2/KDR Quantikine ELISA Kit DVR200
    Enlarge
    Excellent
      Anonymous 06/23/2017
    Show
    Image Details
     Human VEGF R2/KDR Quantikine ELISA Kit DVR200
    : Human VEGF R2/KDR Quantikine ELISA Kit [DVR200]

    Summary

    Sample TestedHuman cell conditioned medium

    Order Details

    Contact Information

    R&D Systems Guarantee

    Feedback

    Customer Information